Moderna's (MRNA) "Market Perform" Rating Reaffirmed at William Blair

William Blair restated their market perform rating on shares of Moderna (NASDAQ:MRNA - Free Report) in a research report report published on Thursday morning,RTT News reports.

A number of other analysts also recently issued reports on the stock. Evercore ISI set a $50.00 price objective on shares of Moderna in a report on Friday, February 14th. Morgan Stanley cut their price objective on Moderna from $39.00 to $32.00 and set an "equal weight" rating for the company in a report on Wednesday, April 9th. Citigroup started coverage on Moderna in a report on Thursday, March 13th. They set a "neutral" rating and a $40.00 price objective on the stock. JPMorgan Chase & Co. reduced their price target on shares of Moderna from $40.00 to $33.00 and set an "underweight" rating on the stock in a research report on Friday, March 21st. Finally, Barclays cut shares of Moderna from an "overweight" rating to an "equal weight" rating and cut their price objective for the company from $111.00 to $45.00 in a research note on Tuesday, February 18th. Four research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $58.70.

Moderna Stock Up 1.7 %

Shares of MRNA stock traded up $0.41 during trading on Thursday, hitting $25.13. The company had a trading volume of 6,858,667 shares, compared to its average volume of 7,287,020. The stock's 50-day moving average is $30.84 and its two-hundred day moving average is $39.49. The stock has a market capitalization of $9.72 billion, a price-to-earnings ratio of -2.71 and a beta of 2.23. Moderna has a 52 week low of $23.15 and a 52 week high of $170.47.

Institutional Trading of Moderna

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Sentry Investment Management LLC bought a new position in shares of Moderna during the first quarter valued at $31,000. Wilmington Savings Fund Society FSB raised its holdings in Moderna by 295.0% in the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company's stock worth $33,000 after buying an additional 587 shares during the last quarter. Compass Planning Associates Inc bought a new position in shares of Moderna in the fourth quarter worth approximately $37,000. Venturi Wealth Management LLC grew its holdings in shares of Moderna by 286.2% during the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company's stock valued at $37,000 after buying an additional 664 shares during the last quarter. Finally, Crowley Wealth Management Inc. bought a new stake in shares of Moderna during the fourth quarter valued at approximately $41,000. Hedge funds and other institutional investors own 75.33% of the company's stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.